AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01602406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab
Study NCT04132843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobenate Dimeglumine
Description: Given IV
Study NCT04132843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: Given IV
Study NCT04132843 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT02432989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Light-moderate exercise on a stationary bike and leisurely walks.
Study NCT00295022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Pharmaceutical form: Over-encapsulated tablet~* Route of administration: Oral use
Study NCT00295022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: * Pharmaceutical form: Over-encapsulated tablet~* Concentration: 10 mg~* Route of administration: Oral use
Study NCT00295022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Description: * Pharmaceutical form: Over-encapsulated tablet~* Concentration: 5 mg~* Route of administration: Oral use
Study NCT02335190 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: RF ablation will be performed using 2 Nimbus multitined electrodes in a bipolar configuration. The electrodes will be placed along the lateral crest using a leap-frogging technique from the inferomedial aspect of the PSIS to the third transverse sacral tubercle at 1.5-2 cm intervals at the skin surface. A radiofrequency current will be passed for 120 seconds per site resulting in thermal coagulation of the plexus. Prior to performing the thermal lesion, electrical stimulation at 2 Hz and 2.0 V will be administered.
Study NCT02335190 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sensory block
Description: Participants will undergo a lidocaine block of the PSN at the lateral crest under ultrasound guidance. 0.5 mL of 2% lidocaine will be injected from the inferomedial border of the PSIS to the third transverse sacral tubercle at approximately 1.5 cm intervals along the skin surface.
Study NCT02335190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Study NCT02475252 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hysteroscopy on a training model
Description: Diagnostic hysteroscopy on a diagnostic hysteroscopy training model using a pelvic dummy and all surgical instruments also used in the original procedure. The performance of all participants will be scored using an OSATS scoring sheet developed for assessing surgical proficiency.
Study NCT02475252 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hysteroscopy on a training model
Description: Diagnostic hysteroscopy on a diagnostic hysteroscopy training model using a pelvic dummy and all surgical instruments also used in the original procedure. The performance of all participants will be scored using an OSATS scoring sheet developed for assessing surgical proficiency.
Study NCT04042701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (DS-8201a)
Description: Part 1: Two dose levels of DS-8201a (3.2 mg/kg Q3W and 5.4 mg/kg Q3W via intravenous (IV) infusion will be administered for the dose escalation part of the study in combination with pembrolizumab.~Part 2: Once Part 1 of the study is complete and a RDE for DS-8201a has been established, Part 2 will begin. All participants will receive DS-8201a at the RDE in combination with pembrolizumab.
Study NCT04042701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (DS-8201a)
Description: Part 1: Two dose levels of DS-8201a (3.2 mg/kg Q3W and 5.4 mg/kg Q3W via intravenous (IV) infusion will be administered for the dose escalation part of the study in combination with pembrolizumab.~Part 2: Once Part 1 of the study is complete and a RDE for DS-8201a has been established, Part 2 will begin.
Study NCT04042701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: All participants will receive pembrolizumab (200 mg Q3W) via intravenous (IV) infusion prior to DS-8201a in Parts 1 and 2 of the study.
Study NCT03732352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given IV
Study NCT03732352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO
Study NCT03732352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo fludeoxyglucose F-18 PET scan
Study NCT03773172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI6012
Description: MEDI6012 is recombinant human lecithin-cholesterol acyltransferase (rhLCAT), an approximately 60 kilodalton, glycosylated, single-chain protein consisting of 416 amino acids produced via Chinese hamster ovary cell culture. It is being explored as an acute treatment to reduce the risk of recurrent cardiovascular events as an adjunct to the standard of care in patients with acute myocardial infarction (MI). MEDI6012 and ACP501 have the identical amino acid sequence and are therefore considered the same molecular entity.
Study NCT03773172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will mimic the active treatment.
Study NCT03005327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X4P-001
Description: Mavorixafor will be provided as either 25 mg or 100 mg capsules.
Study NCT03010150 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Provide blood samples
Study NCT03010150 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05748847 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrastromal corneal ring segment implantation (Pocket)
Description: Patients in this group are planned to undergo ICRS implantation through a femtosecond laser-assisted pocket creation.~The device creates an intrastromal corneal pocket of 8-mm diameter and a depth of nearly 80% of the corneal thickness at the thinnest location with a superior tunnel incision at 90° of 5-mm width.
Study NCT05748847 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrastromal corneal ring segment implantation (Tunnel)
Description: Patients in this group are planned to undergo ICRS implantation through a femtosecond laser-assisted tunnel creation.~The device creates an intrastromal tunnel with a depth of nearly 80% of the corneal thickness at the site of implantation. The tunnel inner and outer diameters are at 5 and 6 mm from the corneal center, respectively with the incision located at the steepest keratometry axis.
Study NCT04687072 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efgartigimod PH20 SC
Description: Subcutaneous injection with efgartigimod PH20 SC
Study NCT04687072 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PH20 SC
Description: Subcutaneous injection with placebo PH20 SC
Study NCT01604928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178
Description: Oral
Study NCT01604928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tolterodine
Description: Oral
Study NCT01604928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT03158142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine Sulfate 1% Oph Soln
Description: Atropine sulphate 1% ophthalmic solution is both a mydriatic and cycloplegic
Study NCT04120220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heavy Cream
Description: Participants will receive a meal in the form of a fruit-containing shake containing 30 g of fat prepared with heavy cream.
Study NCT04120220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soybean Oil
Description: Participants will receive a meal in the form of a fruit-containing shake containing 30 g of fat prepared with soybean oil.
Study NCT04352374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: a Low-Intensity Aerobic Exercise with Borg scale RPE at 11.
Study NCT04352374 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device guided breathing
Description: The device consists of a control box, headphones and a respiratory rate monitor attached as a sensor belt around the user's chest.
Study NCT01609660 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Description: 100mg daily for seven days prior to surgery
Study NCT03811379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Drug: Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
Study NCT01638702 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Follow up of complications
Description: Follow up for complications leading or not to removal (occlusion, accidental removal, infection, catheter related thrombosis, leaking, pain...)
Study NCT01638702 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow up of complications
Description: Follow up for complications leading or not to removal (occlusion, accidental removal, infection, catheter related thrombosis, leaking, pain...)
Study NCT02110420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 10mg will be administered as a single dose
Study NCT02110420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 30mg will be administered as a single dose
Study NCT02110420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 60mg will be administered as a single dose
Study NCT02110420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 120mg will be administered as a single dose
Study NCT02110420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 240mg will be administered as a single dose
Study NCT02110420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 10mg will be administered daily for 14 days
Study NCT02880878 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Surgical Hematoma Evacuation
Description: Early Minimally Invasive Parafascicular Surgery (MIPS)
Study NCT02042950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Starting dose: 20 mg/m2 by vein on Days 1 and 2 in Cycle 1 followed by 56 mg/m\^2 for each subsequent dose thereafter) on days 1 and 2, 8 and 9, 15 and 16 of a 28-day cycle (following cycle 12 carfilzomib given on days 1 and 2 and 15 and 16 only).
Study NCT02157285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Mentor Counseling
Description: Peer mentoring will entail the peer mentor describing her positive experience with her LARC method. The participant will then have a chance to ask any experience related questions to the mentor. Any clinical inquiries or questions the mentor does not feel comfortable answering, she will defer to the contraceptive counselor/ physician who will be subsequently providing the routine counseling. The entire peer mentor encounter should not last more than 10 minutes.
Study NCT02222545 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OMS721
Study NCT01468194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing procedure 1
Description: inhalation during one step, exhalation during the next step
Study NCT01468194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing procedure 2
Description: inhalation and exhalation during one step
Study NCT05225844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab ，200mg/㎡，d1，ivgtt，every 21 days as a cycle
Study NCT05225844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Apatinib Mesylate，250mg/㎡，po，d1-5 on/d2 off，every 21 days as a cycle
Study NCT04001218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of hypertonic saline
Description: Painful condition: Participants will be injected in a neck muscle with 0.5ml of hypertonic saline (5.8%)
Study NCT04001218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of Isotonic saline
Description: Control condition: Participants will be injected in a neck muscle with 0.5ml isotonic saline (0.9%)
Study NCT01496963 — intervention group
Intervention type: OTHER
Intervention: Physician standard-of-care according to ESC/ERS Guidelines
Description: Physician standard-of-care
Study NCT02389725 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: disposable elastic tourniquet
Description: Comparison of first time peripheral IV access success rate between the standard elastic tourniquet and a blood pressure cuff.
Study NCT02389725 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: blood pressure cuff
Description: Comparison of first time peripheral IV access success rate between the standard elastic tourniquet and a blood pressure cuff.
Study NCT06350370 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Natural orifice specimen extraction
Description: We perform laparoscopic colorectal cancer resection, intracorporeal anastomosis and transanal or transvaginal specimen extraction
Study NCT02110420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 30mg will be administered daily for 14 days
Study NCT01102257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 EFA Supplement
Description: The total daily dose from the 5 capsules in treatment group will be 3.0 grams of omega-3 EFAs comprised of:~2000 mg EPA 1000 mg DHA
Study NCT01102257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olive Oil
Description: Placebo group will take 5 capsules a day containing 3.0 grams of olive oil
Study NCT02110420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 60mg will be administered daily for 14 days
Study NCT02110420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 120mg will be administered daily for 14 days
Study NCT02110420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 240mg will be administered daily for 14 days
Study NCT02110420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered once daily for up to 14 days depending on the Part of the study
Study NCT03804229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butylphthalide soft capsule
Description: 700 subjects are randomly divided into two groups by 1:1. About 350 patients in the active group take two pills(100mg each) of Butylphthalide soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.
Study NCT03804229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo soft capsule
Description: 700 subjects are randomly divided into two groups by 1:1. About 350 patients in the active group take two pills of placebo soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.
Study NCT02110420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 480mg will be administered as a single oral dose
Study NCT02110420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 720mg will be administered as a single oral dose
Study NCT03836183 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pleuropulmonary ultrasound with clinical examination
Description: Pleuropulmonary ultrasound associate with a clinical examination
Study NCT00860535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparator: Biomarker evaluation
Description: Patients on standard of care treatment will have blood drawn to evaluate biomarker changes in response to treatment with BCR-ABL inhibitors over a \~3.5 month period.~Part I will enroll patients who are beginning treatment with imatinib (recommended dose 400 mg every day \[qd\]), dasatinib (recommended dose 70 mg twice a day \[bid\]), or nilotinib (recommended dose 400 mg bid).~Part II will enroll patients who are changing from imatinib therapy to either dasatinib or nilotinib. A decision to initiate Part II will be made based on analysis of the results of Part I.
Study NCT01551264 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Foot Abduction Brace (FAB)
Description: After clubfoot correction, the participants will wear the FAB 23 hours/day for 3 months and then wean to naps and nighttime (8-12 hours/day) for either 2 or 4 years depending on which arm they are in.
Study NCT00943956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Study NCT00943956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Study NCT00943956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Study NCT00223626 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topiramate
Description: the maximum topiramate test dose is 200 mg/d.
Study NCT00223626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: the maximum topiramate test dose is 200 mg/d.
Study NCT00545961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: mixture, 0.28125 ml/kg twice a day for 7 days
Study NCT00545961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin clavulanate acid
Description: mixture 0.28125 ml / kg twice a day for 7 days
Study NCT02701010 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured training and leaflet
Description: The patients who were given both explanatory verbal instructions of the educational leaflet on the structured behavioural therapy for iOAB by continence nurse and the educational leaflet were included in this group.
Study NCT02701010 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured training
Description: The patients who were given only explanatory verbal instructions of the educational leaflet on the structured behavioural therapy by continence nurse were included in this group.
Study NCT02701010 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Leaflet
Description: The patients who were given only educational leaflet were included in this group.
Study NCT02110420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001 480mg will be administered daily for 14 days
Study NCT00943956 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy
Study NCT00788957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab for intravenous infusion
Study NCT02701010 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: Patients who were given unstructured explanations about continence care by a healthcare worker were included in control group.
Study NCT01870362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic (Inersan)
Study NCT01870362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00788957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panitumumab
Description: Panitumumab for intravenous infusion
Study NCT00788957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganitumab
Description: Ganitumab for intravenous infusion
Study NCT00788957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilotumumab
Description: Rilotumumab for intravenous infusion
Study NCT00992680 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROX Anastomotic Coupler System (ACS)
Description: The ACS will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein)
Study NCT03931681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKI-179
Description: OKI-179 single agent
Study NCT01819246 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aphersis Treatment Arm
Study NCT01819246 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Arm
Study NCT01653015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Inactivated Vaccine
Description: Influenza vaccination, 0.5 ml dose administered intramuscularly. Previously unvaccinated children who are less than 9 years of age at the time of immunization will receive a second 0.5 ml dose four weeks later.
Study NCT02719990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somavaratan
Description: Long-acting recombinant human growth hormone therapy administered subcutaneously twice-monthly
Study NCT03295513 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Veneered zirconia
Description: he use of veneered zirconia is well documented in the literatures as successful restoration modality. A two Clinical performance of two different CAD/CAM-fabricated ceramic crowns revealed no chipping for veneered zirconia
Study NCT03295513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monolithic zirconia
Description: Monolithic zirconia product presented a new generation of polycrystalline material by which full anatomical crowns and bridges can be produced